Health
Promising Data for Preop Checkpoint Inhibition in NSCLC – MedPage Today
Major response rate of 21%, encouraging survival with single-agent atezolizumab
A fifth of patients with operable early-stage non-small cell lung cancer (NSCLC) had major pathologic responses (MPR) and more than 40% had pathologic downstaging after neoadjuvant atezolizumab (Tecentriq), a prospective multicenter trial showed.
Results showed that 30 of 144 evaluable patients attained MPR, including pathologic complete response (pCR) in 10 patients. Downstaging occurred in 66 of 155 evaluable patients following preoperative treatment with atezolizumab, and 29 patients had upstaging…
-
Noosa News8 hours agoHow Lily Steele-Park took her rapist to court and won
-
General22 hours ago‘Potential’ hacker contacts Qantas over data breach
-
Business13 hours agoFord CEO makes stunning prediction about artificial intelligence
-
Noosa News22 hours agoDarling Downs Zoo gives update on woman who lost her arm in lion attack